Mydecine Innovations Group Inc C.MYCO

Alternate Symbol(s): MYCOF

Mydecine Innovations Group Inc. is a Canada-based biotechnology company. The Company is engaged in developing medications and therapies to address mental health disorders, such as nicotine addiction and posttraumatic stress disorder (PTSD). The Company conducts research and development on second generation compounds in Canada with a focus on developing and commercializing psychedelic-inspired regulated medicines. The Company has two lead 3,4-Methylenedioxymethamphetamine (MDMA) candidates. The Company is channeling its MYCO-005, MYCO-006, and MYCO-007 families of patent-pending second-generation MDMA and Psilocybin analogs through Applied Pharmaceutical Innovation (API). It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.

CSE:MYCO - Post by User

Mydecine Innovations Group Inc

Bullboard Posts

Comment by jmc777on Apr 04, 2019 12:26pm

33 Views

Post# 29582572

RE:$NF's revenues are growing monthly! Call the CEO

Ok pal.. Stop with the bs. If revenue was growing they wouldn't do a RS. When are revenues going to be announced anyway? I bet they don't make more than a few grand.

Bullboard Posts

A Look into the Future of Chronic Pain Management